Yousif Capital Management LLC Cuts Position in Organon & Co. (NYSE:OGN)

Yousif Capital Management LLC trimmed its position in Organon & Co. (NYSE:OGN) by 2.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 78,186 shares of the company’s stock after selling 1,976 shares during the quarter. Yousif Capital Management LLC’s holdings in Organon & Co. were worth $1,164,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of OGN. Norges Bank purchased a new stake in shares of Organon & Co. during the 4th quarter valued at about $25,258,000. Magnetar Financial LLC raised its holdings in shares of Organon & Co. by 560.2% during the 4th quarter. Magnetar Financial LLC now owns 1,734,434 shares of the company’s stock valued at $25,878,000 after buying an additional 1,471,731 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Organon & Co. during the 4th quarter valued at about $11,892,000. Dimensional Fund Advisors LP raised its holdings in shares of Organon & Co. by 23.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,284,408 shares of the company’s stock valued at $48,999,000 after buying an additional 629,191 shares during the period. Finally, Invesco Ltd. raised its holdings in shares of Organon & Co. by 44.6% during the 4th quarter. Invesco Ltd. now owns 2,034,780 shares of the company’s stock valued at $30,359,000 after buying an additional 627,944 shares during the period. 77.43% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

OGN has been the topic of several analyst reports. BNP Paribas upgraded Organon & Co. to a “strong-buy” rating in a report on Thursday, May 22nd. Morgan Stanley dropped their target price on Organon & Co. from $15.00 to $10.00 and set an “equal weight” rating on the stock in a report on Monday, May 5th. Piper Sandler dropped their target price on Organon & Co. from $24.00 to $18.00 and set an “overweight” rating on the stock in a report on Thursday, May 15th. Finally, Evercore ISI downgraded Organon & Co. from an “outperform” rating to an “inline” rating in a report on Friday, May 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Organon & Co. currently has an average rating of “Moderate Buy” and an average price target of $18.00.

Insider Transactions at Organon & Co.

In related news, CFO Matthew M. Walsh bought 11,400 shares of the firm’s stock in a transaction that occurred on Monday, May 5th. The stock was purchased at an average price of $8.82 per share, for a total transaction of $100,548.00. Following the transaction, the chief financial officer now directly owns 144,484 shares of the company’s stock, valued at approximately $1,274,348.88. This represents a 8.57% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel Karp bought 3,500 shares of the stock in a transaction on Tuesday, May 6th. The shares were bought at an average cost of $8.24 per share, for a total transaction of $28,840.00. Following the purchase, the vice president now owns 46,669 shares in the company, valued at $384,552.56. This trade represents a 8.11% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders bought 102,345 shares of company stock worth $902,430. 1.40% of the stock is currently owned by corporate insiders.

Organon & Co. Price Performance

OGN stock opened at $9.87 on Wednesday. The company has a quick ratio of 1.15, a current ratio of 1.67 and a debt-to-equity ratio of 16.49. Organon & Co. has a 52-week low of $8.01 and a 52-week high of $23.10. The stock’s 50 day moving average is $10.00 and its two-hundred day moving average is $13.33. The company has a market capitalization of $2.56 billion, a PE ratio of 3.43, a P/E/G ratio of 1.08 and a beta of 0.58.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, May 1st. The company reported $1.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.13. Organon & Co. had a return on equity of 227.43% and a net margin of 11.92%. The company had revenue of $1.51 billion for the quarter, compared to the consensus estimate of $1.53 billion. During the same period in the previous year, the business earned $1.22 EPS. Organon & Co.’s revenue for the quarter was down 6.7% compared to the same quarter last year. Analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 12th. Stockholders of record on Monday, May 12th were given a $0.02 dividend. The ex-dividend date was Monday, May 12th. This represents a $0.08 annualized dividend and a dividend yield of 0.81%. Organon & Co.’s payout ratio is 2.78%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.